Editorial: Equity in cancer care

Jorge J. NievaFrontiers in Oncology 2024 · DOI · OpenAlex

Abstract

Equity in cancer care is a global challenge, with different patient populations experiencing significantly different average outcomes. These disparities are not unique to any one nation or healthcare system but result from a complex interplay of economic factors, disease comorbidities, educational differences, and exposure to political crises. This Research Topic in Frontiers in Oncology presents a collection of manuscripts that identify opportunities for improvement and address the difficult problems inherent in achieving equitable care. While solutions—such as providing marginalized groups with the resources available to advantaged ones—may seem straightforward, the primary challenge lies in securing the resources and navigating the logistical hurdles required for implementation.

Introduction

The "cancer gap" is a persistent global phenomenon where patient outcomes vary significantly based on population demographics. These disparities are driven by a confluence of systemic factors, including economic barriers, educational gaps, and varying prevalence of comorbidities. Jorge J. Nieva argues that while identifying these disparities is relatively straightforward, correcting them is notoriously difficult. This editorial synthesizes research that addresses the gap between recognizing a solution and the practical hurdles of implementation, such as neighborhood-level heterogeneity and systemic segregation.

Addressing the Implementation Gap

A recurring theme in this Research Topic is the need for localized and inclusive strategies. For instance, improving health literacy among women can enhance screening mammography rates (Poon et al.), yet such interventions must account for neighborhood-level heterogeneity that requires unique, "block-to-block" approaches (Layne et al.).

Furthermore, disparities often begin at the policy level. Standard screening criteria may be designed around the "average" (often white) patient, inadvertently excluding minority groups who might present with different risk profiles. Olazagasti et al. suggest that altering screening indications is a necessary step toward inclusivity. Similarly, addressing population segregation and making screening more accessible—such as covering sedation costs for colonoscopies (Zhuo et al.)—can significantly improve outcomes for underserved populations.

Biological and Comorbid Factors

Equity in care also requires addressing biological differences and the uneven distribution of comorbidities. Diabetes and cardiac disease, which are not distributed equally across populations, fundamentally impact cancer care efficacy (Ashing et al.; Patel et al.). Interestingly, Olateju et al. found that for small cell lung cancer, these comorbidities did not necessarily lead to inferior outcomes in minority populations, suggesting a complex interaction between biology and clinical care.

A critical limitation in current research is the reliance on laboratory models and cell lines derived from a narrow demographic segment. This "biological blind spot" means we lack crucial data on how cancer mediators, such as miRNAs, are differentially expressed across various ethnic groups. Without diversifying our laboratory models, we risk developing treatments that are inherently less effective for marginalized populations.

The editorial summarizes several impactful findings and sobering trends from the broader research topic:

  • Screening Accessibility: Simple logistical fixes, like covering the cost of sedation for colonoscopies, can significantly improve screening rates among the poor.
  • Global Deterioration: Despite the end of apartheid, breast cancer mortality in South Africa has shown worsening trends. Similarly, the research highlights the devastating impact of drug shortages on cancer patients in Lebanon, illustrating how political crises exacerbate health inequities.
  • Targeted Interventions: While targeted interventions aimed at minority populations are necessary, they have been notoriously difficult to conduct, often due to historical segregation and mistrust.

Conclusion and Future Directions

The research presented highlights that technical solutions are only half the battle; the other half is the collective will and political wisdom to apply those solutions where they are needed most. Future efforts must focus on:

  1. Diversifying Laboratory Models: Developing cell lines and genomic signatures that reflect the global diversity of cancer patients.
  2. Granular Public Health: Moving toward hyper-local health interventions that account for neighborhood-level segregation and heterogeneity.
  3. Policy Reform: Re-evaluating screening indications to ensure they are inclusive of the risk profiles of minority populations.

Ultimately, achieving equity in cancer care requires moving beyond identifying disparities toward the active allocation of resources to bridge the implementation gap.

Summary updated

Abstract

Equity in cancer careDifferent patient populations will experience different average outcomes from their cancer.This experience is not unique to any one nation or healthcare system but is seen worldwide and can result from population differences in economic factors, disease comorbidities, educational differences, and exposure to economic and political crises.Each of the manuscripts in this Research Topic represents an opportunity for improvement.After all, if we can see one group doing worse than another regarding cancer outcomes, it is relatively easy to imagine a solution that simply gives what the advantaged group has to those who lack it.In this Research Topic of Frontiers in Oncology dedicated to Equity in Cancer Care, we are presented with experiences worldwide that address these difficult problems.While seeing a solution may be easy, finding the resources to correct them is often where the challenge lies.Sometimes the solution is simply to improve health literacy among women to improve rates of screening mammography (Poon et al.).But such interventions may be difficult to implement across populations where local effects of neighborhoods create heterogeneity in the population that call for unique approaches that may need to vary from block to block (Layne et al.).A better approach may be to alter the criteria for screening in the first place, to ensure that the indications for screening do not leave out minority groups (Olazagasti et al.).Meanwhile, segregation of populations can impact other health behaviors besides screening and ending such segregation may be a potential solution (Pichardo et al.), as targeted interventions aimed at minority populations have been notoriously difficult to conduct (Pichardo et al.).Simple solutions, such as making screening easier on patients, by covering sedation along with screening colonoscopy for example, may go a long way to improving screening rates among the poor (Zhuo et al.).Other solutions may need to be rooted in biological differences between groups.A comorbidity such as diabetes and all its impacts on cancer care is not evenly distributed in patient populations and might make care for some groups inferior (Ashing et al.), though another study in this Research Topic found that for small cell lung cancer at least, those effects did not lead to inferior outcomes in minority populations at higher risk for diabetes (Olateju et al.).Cardiac disease is also unevenly distributed as a comorbidity in cancer patients and optimal outcomes for cancer will not be achieved if this disparity is not addressed (Patel et al.).
BibTeX
@inproceedings{nieva2024editorial,
  author = {Jorge J. Nieva},
  title = {{Editorial: Equity in cancer care}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2023.1346785},
}
Figure